Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.890
-0.060 (-3.08%)
At close: Mar 3, 2026, 4:00 PM EST
1.890
0.00 (0.00%)
After-hours: Mar 3, 2026, 4:22 PM EST
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Lineage Cell Therapeutics stock have an average target of 4.67, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 147.09% from the current stock price of 1.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +5.82% | Feb 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +5.82% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +376.19% | Nov 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +5.82% | Aug 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +5.82% | Aug 14, 2025 |
Financial Forecast
Revenue This Year
10.10M
from 9.50M
Increased by 6.32%
Revenue Next Year
22.67M
from 10.10M
Increased by 124.49%
EPS This Year
-0.31
from -0.09
EPS Next Year
-0.07
from -0.31
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 12.2M | 36.0M | ||||
| Avg | 10.1M | 22.7M | ||||
| Low | 6.1M | 3.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 28.6% | 256.5% | ||||
| Avg | 6.3% | 124.5% | ||||
| Low | -36.0% | -67.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.15 | -0.04 | ||||
| Avg | -0.31 | -0.07 | ||||
| Low | -0.41 | -0.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.